Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Background Ipilimumab is a cytotoxic T lymphocyte antigen 4 (CTLA-4) blocking monoclonal antibody indicated for the treatment of unresectable or metastatic melanoma. In phase III studies, ipilimumab has been shown to increase overall survival by 3.6 months, progression free survival (PFS) by 2.7 months with a response rate of 9.5% with the induction dosing regimen: intravenous administration 3 mg/kg every 3 weeks, for a total of 4 applications.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.